Evidence map›Paper›PMID 27765932›Full record

ArticleOncotarget2016

Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.

Yan Long, Wen-Bin Tsai, Jeffrey T Chang, Marcos Estecio, Medhi Wangpaichitr, Naramol Savaraj, Lynn G Feun, Helen H W Chen, Macus Tien Kuo

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 63 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Nitrogen Isotope Effects in Urea Metabolism: From Biochemistry toInternational journal of molecular sciences · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Yan LongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wen-Bin TsaiDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeffrey T ChangDepartment of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Marcos EstecioDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Medhi WangpaichitrSylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Naramol SavarajSylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Lynn G FeunSylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Helen H W ChenDepartment of Radiation Oncology, National Cheng Kung University, National Cheng Kung University Hospital, College of Medicine, Tainan, Taiwan.
Macus Tien KuoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · USUniversity of Miami · USNational Cheng Kung University Hospital · TWSylvester Comprehensive Cancer Center · USThe University of Texas Health Science Center at Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Improving the Efficacy of Cisplatin-Based Cancer ChemotherapyR01CA149260 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KUO, MACUS T · 2010 to 2014
$1.6M
Mechanism of Resistance to Arginine Deiminase Therapy in Advance MelanomaR01CA152197 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KUO, MACUS T · 2010 to 2013
$1.3M
Metabolic reprogramming: A new paradigm for targeting cisplatin resistant cellsIK2BX001289 · VA · MIAMI VA HEALTH CARE SYSTEM · PI WANGPAICHITR, MEDHI · 2013 to 2017
–
BLRD VA IK2 BX001289NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA149260NCI NIH HHS R01 CA152197
6 · The paper itself

Abstract

Many human tumors require extracellular arginine (Arg) for growth because the key enzyme for de novo biosynthesis of Arg, argininosuccinate synthetase 1 (ASS1), is silenced. These tumors are sensitive to Arg-starvation therapy using pegylated arginine deiminase (ADI-PEG20) which digests extracellular Arg. Many previous studies reported that ASS1 silencing is due to epigenetic inactivation of ASS1 expression by DNA methylation, and that the demethylation agent 5-aza-deoxycytidine (Aza-dC) can induce ASS1 expression. Moreover, it was reported that cisplatin suppresses ASS1 expression through ASS1 promoter methylation, leading to synthetic lethality to ADI-PEG20 treatment. We report here that cisplatin supppresses ASS1 expression is due to upregulation of HIF-1α and downregulation of c-Myc, which function as negative and positive regulators of ASS1 expression, respectively, by reciprocal bindings to the ASS1 promoter. In contrast, we found that Aza-dC induces ASS1 expression by downregulation of HIF-1α but upregulation of c-Myc. We further demonstrated that the clock protein DEC1 is the master regulator of HIF-1α and c-Myc that regulate ASS1. cDDP upregulates DEC1, whereas Aza-dC suppresses its expression. Using two proteasomal inhibitors bortezomib and carfilzomib which induce HIF-1α accumulation, we further demonstrated that HIF-1α is involved in ASS1 silencing for the maintenance of Arg auxotrophy for targeted Arg-starvation therapy.

Indexed as

DNA MethylationPromoter Regions, GeneticAntineoplastic Combined Chemotherapy ProtocolsArginineArgininosuccinate SynthaseBasic Helix-Loop-Helix ProteinsCell Line, TumorCell SurvivalCisplatinDose-Response Relationship, DrugDown-RegulationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHomeodomain ProteinsHumansADI PEG20ArginineArgininosuccinate SynthaseBasic Helix-Loop-Helix ProteinsBHLHE40 protein, humanCisplatinHIF1A protein, humanHistone Deacetylase InhibitorsHomeodomain ProteinsHydrolasesHypoxia-Inducible Factor 1, alpha SubunitMYC protein, humanPolyethylene GlycolsProteasome InhibitorsProto-Oncogene Proteins c-mycarginine-starvationASS1cisplatinDEC1-HIF-1α-c-Myc axisDNA methylation

Identifiers

PMID27765932
PMCPMC5347722
OpenAlexW2524894273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.